NF-kappaB in critical diseases: a bad guy?
Senftleben
Uwe
U
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D016638:Critical Illness / Q000628:therapy; D004195:Disease Models, Animal; D005786:Gene Expression Regulation; D006706:Homeostasis; D006801:Humans; D007249:Inflammation; D051379:Mice; D009102:Multiple Organ Failure / Q000139:chemically induced / Q000276:immunology* / Q000517:prevention & control*; D016328:NF-kappa B / Q000276:immunology*; D010084:Oxidation-Reduction; D011392:Proline / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D015398:Signal Transduction / Q000276:immunology*; D013859:Thiocarbamates / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D014157:Transcription Factors; D015054:Zymosan
D000975:Antioxidants; D016328:NF-kappa B; D013859:Thiocarbamates; D014157:Transcription Factors; C066229:prolinedithiocarbamate; D015054:Zymosan; D011392:Proline